Patents by Inventor James Andrew Johnson

James Andrew Johnson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8637491
    Abstract: A series of thieno[2,3-b]pyridine derivatives, attached at the 2-position to a substituted anilino moiety, which are substituted in the 3-position by a carbonyl group linked to a pyrrolidin-1-yl ring which in turn forms part of a heteroatom-containing fused bicyclic ring system, being selective inhibitors of human MEK (MAPKK) enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, proliferative (including oncological) and nociceptive conditions.
    Type: Grant
    Filed: December 17, 2010
    Date of Patent: January 28, 2014
    Assignee: UCB Pharma S.A.
    Inventors: James Andrew Johnson, Daniel Christopher Brookings, Barry John Langham, Judi Charlotte Neuss, Joanna Rachel Thorne
  • Patent number: 8604051
    Abstract: Novel processes for the preparation of thieno[2,3-b]pyridine derivatives which are substituted in the 2-position by a substituted anilino moiety and intermediates thereto are provided. The compounds prepared by the present processes may be useful, for example, as selective inhibitors of human MEK (MAPKK) enzymes, and are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, proliferative (including oncological) and nociceptive conditions. The present processes may offer improved yields, chemical or stereochemical purity, ease of preparation and/or isolation of intermediates and final product, and more industrially useful reaction conditions and workability.
    Type: Grant
    Filed: February 6, 2013
    Date of Patent: December 10, 2013
    Assignee: UCB Pharma S.A.
    Inventors: Martin Clive Hutchings, Sarah Catherine Archibald, Daniel Christopher Brookings, Jeremy Martin Davis, James Andrew Johnson, Barry John Langham, Judi Charlotte Neuss
  • Patent number: 8394822
    Abstract: A series of thieno[2,3-b]pyridine derivatives which are substituted in the 2-position by a substituted anilino moiety, being selective inhibitors of human MEK (MAPKK) enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, proliferative (including oncological) and nociceptive conditions.
    Type: Grant
    Filed: September 5, 2012
    Date of Patent: March 12, 2013
    Assignee: UCB Pharma, S.A.
    Inventors: Martin Clive Hutchings, Sarah Catherine Archibald, Daniel Christopher Brookings, Jeremy Martin Davis, James Andrew Johnson, Barry John Langham, Judi Charlotte Neuss
  • Patent number: 8350037
    Abstract: A series of thieno[2,3-b]pyridine derivatives which are substituted in the 2-position by a substituted anilino moiety, being selective inhibitors of human MEK (MAPKK) enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, proliferative (including oncological) and nociceptive conditions.
    Type: Grant
    Filed: January 22, 2010
    Date of Patent: January 8, 2013
    Assignee: UCB Pharma, S.A.
    Inventors: James Andrew Johnson, Daniel Christopher Brookings, Martin Clive Hutchings, Barry John Langham, Judi Charlotte Neuss
  • Publication number: 20120329774
    Abstract: A series of thieno[2,3-b]pyridine derivatives which are substituted in the 2-position by a substituted anilino moiety, being selective inhibitors of human MEK (MAPKK) enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, proliferative (including oncological) and nociceptive conditions.
    Type: Application
    Filed: September 5, 2012
    Publication date: December 27, 2012
    Applicant: UCB Pharma S.A.
    Inventors: Clive Martin Hutchings, Sarah Catherine Archibald, Daniel Christopher Brookings, Jeremy Martin Davis, James Andrew Johnson, Barry John Langham, Judi Charlotte Neuss
  • Patent number: 8283359
    Abstract: A series of thieno[2,3-b]pyridine derivatives which are substituted in the 2-position by a substituted anilino moiety, being selective inhibitors of human MEK (MAPKK) enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, proliferative (including oncological) and nociceptive conditions.
    Type: Grant
    Filed: July 30, 2008
    Date of Patent: October 9, 2012
    Assignee: UCB Pharma S.A.
    Inventors: Martin Clive Hutchings, Sarah Catherine Archibald, Daniel Christopher Brookings, Jeremy Martin Davis, James Andrew Johnson, Barry John Langham, Judi Charlotte Neuss
  • Publication number: 20110172191
    Abstract: A series of thieno[2,3-b]pyridine derivatives, attached at the 2-position to a substituted anilino moiety, which are substituted in the 3-position by a carbonyl group linked to a pyrrolidin-1-yl ring which in turn forms part of a heteroatom-containing fused bicyclic ring system, being selective inhibitors of human MEK (MAPKK) enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, proliferative (including oncological) and nociceptive conditions.
    Type: Application
    Filed: December 17, 2010
    Publication date: July 14, 2011
    Applicant: UCB Pharma S.A.
    Inventors: James Andrew Johnson, Daniel Christopher Brookings, Barry John Langham, Judi Charlotte Neuss, Joanna Rachel Thorne
  • Publication number: 20100179124
    Abstract: A series of thieno[2,3-b]pyridine derivatives which are substituted in the 2-position by a substituted anilino moiety, being selective inhibitors of human MEK (MAPKK) enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, proliferative (including oncological) and nociceptive conditions.
    Type: Application
    Filed: January 22, 2010
    Publication date: July 15, 2010
    Applicant: UCB Pharma S.A.
    Inventors: James Andrew Johnson, Daniel Christopher Brookings, Martin Clive Hutchings, Barry John Langham, Judi Charlotte Neuss
  • Publication number: 20090149437
    Abstract: A series of thieno[2,3-b]pyridine derivatives which are substituted in the 2-position by a substituted anilino moiety, being selective inhibitors of human MEK (MAPKK) enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, proliferative (including oncological) and nociceptive conditions.
    Type: Application
    Filed: July 30, 2008
    Publication date: June 11, 2009
    Applicant: UCB PHARMA S.A.
    Inventors: Clive Martin Hutchings, Sarah Catherine Archibald, Daniel Christopher Brookings, Jeremy Martin Davis, James Andrew Johnson, Barry John Langham, Judi Charlotte Neuss